[{"id":"4bcfb962-b8dd-4377-826e-bc8e7b62607e","acronym":"CYNK001GBM02","url":"https://clinicaltrials.gov/study/NCT05218408","created_at":"2022-02-05T18:28:25.292Z","updated_at":"2024-07-02T16:35:55.355Z","phase":"Phase 1/2","brief_title":"CYNK-001 IV and IC in Combination With IL2 in Surgical Eligible Recurrent GBM With IDH-1 Wild Type","source_id_and_acronym":"NCT05218408 - CYNK001GBM02","lead_sponsor":"Celularity Incorporated","biomarkers":" IDH1","pipe":" | ","alterations":" IDH wild-type","tags":["IDH1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e IDH wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • taniraleucel (CYNK-001)"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 03/08/2022","start_date":" 03/08/2022","primary_txt":" Primary completion: 02/01/2024","primary_completion_date":" 02/01/2024","study_txt":" Completion: 05/01/2024","study_completion_date":" 05/01/2024","last_update_posted":"2023-02-16"}]